Anderson JJ - Search Results

1

Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis.

Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Anderson JJ, et al. Arthritis Rheum. 2001 Aug;44(8):1876-86. doi: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F. Arthritis Rheum. 2001. PMID: 11508441 Free article.

2

Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.

Anderson JJ, Bolognese JA, Felson DT. Anderson JJ, et al. Arthritis Rheum. 2003 Nov;48(11):3031-8. doi: 10.1002/art.11293. Arthritis Rheum. 2003. PMID: 14613263 Free article.

3

The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis.

Felson DT, Anderson JJ, Meenan RF. Felson DT, et al. Among authors: anderson jj. Arthritis Rheum. 1994 Oct;37(10):1487-91. doi: 10.1002/art.1780371012. Arthritis Rheum. 1994. PMID: 7945474

4

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, et al. Felson DT, et al. Among authors: anderson jj. Arthritis Rheum. 1993 Jun;36(6):729-40. doi: 10.1002/art.1780360601. Arthritis Rheum. 1993. PMID: 8507213

5

Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?

Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Felson DT, et al. Among authors: anderson jj. Arthritis Rheum. 1998 Sep;41(9):1564-70. doi: 10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M. Arthritis Rheum. 1998. PMID: 9751088

6

Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.

Anderson JJ, Wells G, Verhoeven AC, Felson DT. Anderson JJ, et al. Arthritis Rheum. 2000 Jan;43(1):22-9. doi: 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9. Arthritis Rheum. 2000. PMID: 10643696 Free article.

7

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

Felson DT, Anderson JJ, Meenan RF. Felson DT, et al. Among authors: anderson jj. Arthritis Rheum. 1992 Oct;35(10):1117-25. doi: 10.1002/art.1780351003. Arthritis Rheum. 1992. PMID: 1358078

8

Secular changes in published clinical trials of second-line agents in rheumatoid arthritis.

Anderson JJ, Felson DT, Meenan RF. Anderson JJ, et al. Arthritis Rheum. 1991 Oct;34(10):1304-9. doi: 10.1002/art.1780341015. Arthritis Rheum. 1991. PMID: 1930319

9

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.

Felson DT, Anderson JJ, Meenan RF. Felson DT, et al. Among authors: anderson jj. Arthritis Rheum. 1990 Oct;33(10):1449-61. doi: 10.1002/art.1780331001. Arthritis Rheum. 1990. PMID: 1977391 Clinical Trial.

10

Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials.

Felson DT, Anderson JJ, Meenan RF. Felson DT, et al. Among authors: anderson jj. Arthritis Rheum. 1990 Jan;33(1):140-9. doi: 10.1002/art.1780330119. Arthritis Rheum. 1990. PMID: 2405863 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

376 results

Search Page